---
layout: default
title: Fulvestrant
parent: Model Prediction Only (L5)
nav_order: 286
evidence_level: L5
indication_count: 10
---

# Fulvestrant
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Fulvestrant: From Hormone Receptor-Positive Breast Cancer to HIV Infectious Disease

*(Note: the evidence pack itself contains no original indication data for Fulvestrant — this is flagged as a Blocking/High data gap in the record. "Hormone receptor-positive breast cancer" is included here as established general pharmacological knowledge about this molecule, not as data drawn from this evidence pack.)*

## One-Sentence Summary

Fulvestrant is a selective oestrogen receptor degrader (SERD) with an established role in hormone receptor-positive breast cancer, though this evidence pack does not itself contain confirmed original-indication or mechanism-of-action records. The TxGNN model's top prediction for this drug is **HIV infectious disease**, but this is currently supported by **zero clinical trials** and only **one weakly related, non-peer-reviewed preprint** that does not actually study Fulvestrant or HIV directly — the evidence base is effectively absent.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in this evidence pack (data gap — see below); generally known as hormone receptor-positive metastatic breast cancer |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack (flagged as data gap DG002). Fulvestrant is broadly known as a pure oestrogen receptor antagonist that promotes receptor degradation, but no mechanistic detail linking this pathway to HIV pathophysiology is provided here.

The model-generated rationale attached to this prediction is itself sceptical of the link: the single supporting publication concerns HTLV-1-associated myelopathy — a distinct retrovirus and a distinct neuroinflammatory disease — and does not evaluate Fulvestrant or HIV. The rationale explicitly notes this is likely a case of the knowledge graph over-extending a loose "retrovirus/immune signalling" association rather than genuine mechanistic evidence for a Fulvestrant–HIV relationship.

Taken together, this prediction currently rests on the TxGNN similarity score alone, with no corroborating clinical, trial, or on-topic literature evidence.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [40343334](https://pubmed.ncbi.nlm.nih.gov/40343334/) | 2025 | Cohort/omics (preprint, not peer-reviewed) | Research Square | Multi-cohort cross-omics analysis of HTLV-1-associated myelopathy (HAM), a neuroinflammatory disease caused by a different retrovirus (HTLV-1, not HIV). The paper explores disease mechanisms and therapeutic targets for HAM generally; it does not study Fulvestrant or HIV, and should be treated as tangential rather than direct supporting evidence. |

## UK Market Information

Fulvestrant is not currently marketed under this record: 0 marketing authorisations are on file and market status is recorded as "Not marketed." No product, dosage form, or approved indication data is available to tabulate.

## Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

*(No drug interaction, warning, or contraindication data was returned for this record — a DDI query specifically returned no results.)*

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted HIV indication is unsupported at present — there are no clinical trials, and the sole literature hit concerns a different virus (HTLV-1) and does not address Fulvestrant. Combined with the absence of UK marketing authorisation and a Blocking data gap on safety labelling, this candidate cannot proceed past an initial screening stage.

**To proceed, the following is needed:**
- Fulvestrant's SmPC warnings, contraindications, and safety labelling (currently a Blocking gap — required before any safety assessment)
- Confirmed mechanism-of-action data to assess biological plausibility for an HIV indication
- Confirmed original indication and regulatory history for this drug
- On-topic clinical or preclinical evidence directly evaluating Fulvestrant in HIV-infected populations or models, rather than the currently available HTLV-1 preprint
- A review of whether the "HIV infectious disease" disease-mapping in the knowledge graph is being correctly distinguished from related but distinct retroviral conditions (HTLV-1, SIV, feline AIDS also appear among this drug's top-ranked predictions, suggesting possible ontology/mapping noise worth checking before further investment)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

